L-NAME Inhibits Tumor Cell Progression and Pulmonary Metastasis of R/m HM-SFME-1 Cells by Decreasing NO from Tumor Cells and TNF-alpha from Macrophages
Overview
Affiliations
Highly metastatic ras/myc-transformed serum-free mouse embryo (r/m HM-SFME-1) cells were injected subcutaneously to mice and the effects of Nomega-nitro-L-arginine methyl ester (L-NAME) on the tumor progression and pulmonary metastasis were investigated. In addition, production of nitric oxide (NO), matrix metalloproteinases (MMPs) and tumor necrosis factor-alpha (TNF-alpha) in the tumor cells and in a mouse macrophage-like cell line, J774.1 cells, was analyzed. The increase in footpad thickness was significantly smaller in the mice which were fed the L-NAME containing water (4.24+/-0.39 mg/day/mouse). The number of the tumor cells metastasized to the lungs was smaller in the L-NAME treated mice, although statistical significance was not found. Co-treatment of r/m HM-SFME-1 cells with interferon-gamma (IFN-gamma; 100 U/ml) and lipopolysaccharide (LPS; 0.5 microg/ml) significantly enhanced NO production, and the presence of L-NAME at 1 mM significantly decreased this response. In r/m HM-SFME-1 cells, MMP-2 was undetectable and MMP-9 was also very little in the basal level, and both MMPs were unaffected by the IFN-gamma and/or LPS treatments, not to mention by the L-NAME treatment. In J774.1 cells, any treatment including LPS appeared to enhance MMP-9 production, however, this upregulation was not inhibited by the additional presence of L-NAME. Production of TNF-alpha by J774.1 cells was markedly enhanced with LPS treatment, and this enhancement was significantly reduced in the presence of L-NAME. These results indicate that the inhibitory effects of L-NAME on the tumor cell progression and pulmonary metastasis could be due to suppression of NO from tumor cells and TNF-alpha from macrophages (Mol Cell Biochem, 2007).
Logsdon A, Meabon J, Cline M, Bullock K, Raskind M, Peskind E Sci Rep. 2018; 8(1):11344.
PMID: 30054495 PMC: 6063850. DOI: 10.1038/s41598-018-29341-6.
Perrotta C, Cervia D, Di Renzo I, Moscheni C, Bassi M, Campana L Front Immunol. 2018; 9:1186.
PMID: 29896202 PMC: 5987706. DOI: 10.3389/fimmu.2018.01186.
Pershing N, Yang C, Xu M, Counter C Oncotarget. 2016; 7(27):42385-42392.
PMID: 27285753 PMC: 5173142. DOI: 10.18632/oncotarget.9874.
Whiting C, Castillo A, Haque M, Majid D Am J Physiol Renal Physiol. 2013; 305(7):F1031-41.
PMID: 23926180 PMC: 3798739. DOI: 10.1152/ajprenal.00024.2013.
Coursey T, Chen P, Niederkorn J J Leukoc Biol. 2012; 92(5):939-50.
PMID: 22693246 PMC: 3476238. DOI: 10.1189/jlb.0312122.